TL;DR: Multiple sclerosis is driven by an immune system that attacks the brain’s own myelin, producing waves of neuroinflammation and progressive neurological damage. While disease-modifying therapies remain the cornerstone of treatment, a growing body of evidence suggests that diet meaningfully influences MS disease activity and progression. Vitamin D deficiency is one of the most consistent environmental risk factors for MS, and supplementation may reduce relapse rates. Omega-3 fatty acids dampen the pro-inflammatory cytokine cascades central to MS pathology. The gut microbiome — shaped profoundly by diet — regulates the balance between pro-inflammatory Th17 cells and anti-inflammatory regulatory T cells, a balance that is disrupted in MS. High sodium intake promotes Th17 differentiation and worsens autoimmune neuroinflammation in both animal models and human studies. The Swank diet, the Wahls Protocol, and the Mediterranean diet each offer partial evidence, but no single dietary intervention has been validated in a large-scale randomized controlled trial as an MS treatment. What the evidence does support is a practical anti-inflammatory dietary framework — rich in fatty fish, colorful vegetables, polyphenols, fermented foods, and adequate vitamin D, while low in ultra-processed food, excess sodium, and saturated fat — as a meaningful adjunct to standard medical care.
Introduction
Multiple sclerosis is a disease of misdirected immunity. In MS, the immune system — designed to protect the body from pathogens — turns against the central nervous system, attacking the myelin sheath that insulates nerve fibers in the brain and spinal cord. The result is disrupted nerve signal transmission, producing symptoms that range from fatigue and cognitive fog to visual disturbances, numbness, weakness, and progressive disability.
MS affects approximately 2.8 million people worldwide, with prevalence varying dramatically by geography and latitude. It is most common in northern Europe, Canada, and the northern United States, and far less common near the equator — a gradient that provided one of the earliest clues that environmental factors, not genetics alone, shape MS risk.
Over the past two decades, the study of MS has undergone a conceptual shift. The disease is no longer viewed solely as an autoimmune attack on myelin. It is increasingly understood as a complex interplay between genetic susceptibility, immune dysregulation, neuroinflammation, neurodegeneration, and environmental exposures — among which diet is emerging as one of the most modifiable and consequential. What a person with MS eats influences systemic inflammation, gut microbiome composition, immune cell differentiation, oxidative stress, and the integrity of the blood-brain barrier. None of these effects replace the need for disease-modifying therapies, but they may alter the trajectory of the disease.
This article examines the evidence for dietary strategies in MS, from the foundational science of demyelination and neuroinflammation to specific nutrients, dietary patterns, and practical frameworks.
MS Pathophysiology: Demyelination and Neuroinflammation
The Myelin Sheath and Why It Matters
Myelin is a lipid-rich substance produced by oligodendrocytes in the central nervous system. It wraps around axons in concentric layers, forming an insulating sheath that enables rapid, efficient electrical signal conduction through a process called saltatory conduction — nerve impulses leap between gaps in the myelin (nodes of Ranvier) rather than traveling continuously along the axon. This makes signal transmission up to 100 times faster than in unmyelinated fibers.
When myelin is damaged or destroyed — as it is in MS — signal transmission slows, becomes unreliable, or fails entirely. The clinical manifestation depends on which nerve fibers are affected: damage to optic nerve myelin produces visual symptoms, damage to spinal cord myelin produces motor and sensory symptoms, and damage to cerebral white matter produces cognitive impairment and fatigue.
The Autoimmune Attack
In MS, autoreactive T cells — particularly CD4+ T helper cells of the Th1 and Th17 subtypes — cross the blood-brain barrier and initiate an inflammatory cascade in the central nervous system. These T cells recognize myelin proteins as foreign and recruit additional immune cells, including macrophages and B cells, to the site of attack. The resulting inflammation produces the characteristic demyelinating lesions visible on MRI.
Th17 cells, which produce the cytokine interleukin-17 (IL-17), have received particular attention in MS research. IL-17 disrupts blood-brain barrier tight junctions, promotes the recruitment of neutrophils and other inflammatory cells into the CNS, and amplifies the inflammatory damage to myelin. Kebir and colleagues (2007), in work published in Nature Medicine, demonstrated that Th17 cells from MS patients could cross the blood-brain barrier more efficiently than other T cell subsets and were enriched in active MS lesions. The balance between pathogenic Th17 cells and anti-inflammatory regulatory T cells (Tregs) — which suppress autoimmune responses — is a central axis of MS immunopathology.
Neurodegeneration Beyond Inflammation
MS was historically conceptualized as a purely inflammatory disease, but it is now clear that neurodegeneration occurs alongside and beyond the acute inflammatory attacks. Axonal transection — the physical severing of nerve fibers — occurs within acute inflammatory lesions. Progressive gray matter atrophy, synaptic loss, and mitochondrial dysfunction contribute to the gradual accumulation of disability in progressive MS, even in the absence of new inflammatory lesions. Trapp and Nave (2008), writing in the Annual Review of Neuroscience, described this dual pathology as intertwined processes: early inflammation drives demyelination and axonal injury, while sustained oxidative stress and energy failure drive progressive neurodegeneration.
This dual nature is relevant to dietary strategy. An optimal dietary approach for MS would address both the inflammatory and the neurodegenerative components — dampening immune-mediated attacks while supporting mitochondrial function, antioxidant defense, and neuronal resilience.
Vitamin D and MS: The Latitude Gradient
The Epidemiological Evidence
The geographic distribution of MS provided the first clue that vitamin D plays a role in the disease. MS prevalence increases with distance from the equator in both hemispheres — a pattern that correlates closely with ultraviolet B (UVB) radiation exposure and, consequently, vitamin D synthesis in the skin. Populations near the equator, where year-round sun exposure maintains higher vitamin D levels, have substantially lower MS rates than populations at higher latitudes.
Munger and colleagues (2004), in a study published in Neurology analyzing data from the Nurses’ Health Study and the Nurses’ Health Study II, found that women with the highest vitamin D intake from supplements (400 IU per day or more) had a 40 percent lower risk of developing MS compared to women with no supplemental vitamin D intake. A subsequent study by Munger and colleagues (2006), published in JAMA, examined serum 25-hydroxyvitamin D levels in US military personnel before MS diagnosis and found that higher vitamin D levels were associated with significantly reduced MS risk — particularly among white individuals. Each 50 nmol/L increase in serum 25(OH)D was associated with a 41 percent reduction in MS risk.
Vitamin D and Disease Activity
Beyond prevention, vitamin D status appears to influence disease activity in people already diagnosed with MS. Several observational studies have found inverse associations between serum vitamin D levels and relapse rates, MRI lesion activity, and disability progression. Ascherio and colleagues (2014), in a study published in JAMA Neurology, followed patients with a first demyelinating event (clinically isolated syndrome) and found that each 50 nmol/L increase in serum vitamin D was associated with a 57 percent lower rate of new active lesions on MRI and a 57 percent lower relapse rate.
The SOLAR trial — a randomized controlled trial published by Hupperts and colleagues (2019) in Neurology — tested high-dose vitamin D3 supplementation (14,000 IU per day) as an add-on to interferon beta-1a in relapsing-remitting MS. The primary endpoint (a combined measure of no evidence of disease activity) did not reach statistical significance, though there was a trend favoring vitamin D. Importantly, the study was likely underpowered, and subgroup analyses suggested benefits in MRI outcomes.
Immunological Mechanisms
Vitamin D is not merely a nutrient involved in calcium metabolism. It is a potent immunomodulator. The active form — 1,25-dihydroxyvitamin D3 (calcitriol) — binds to the vitamin D receptor (VDR), which is expressed on virtually all immune cells, including T cells, B cells, dendritic cells, and macrophages.
Calcitriol shifts immune cell differentiation away from pro-inflammatory Th1 and Th17 phenotypes and toward anti-inflammatory Th2 and regulatory T cell phenotypes — precisely the immunological shift that would be protective in MS. It also promotes the production of the anti-inflammatory cytokine IL-10 and suppresses the production of IL-17, IL-6, and TNF-alpha. Smolders and colleagues (2008), in a review published in the Journal of Neuroimmunology, described vitamin D as a “natural selective immune modulator” with particular relevance to MS pathophysiology.
Practical Implications
Most MS experts now recommend maintaining serum 25(OH)D levels of at least 75-100 nmol/L (30-40 ng/mL), with some advocating for higher targets of 100-150 nmol/L. For many people living at higher latitudes, this requires supplementation — typically 2,000 to 5,000 IU of vitamin D3 per day, adjusted based on blood levels. Dietary sources alone (fatty fish, egg yolks, fortified foods) rarely provide sufficient vitamin D in the absence of sun exposure.
Omega-3 Fatty Acids and MS
Anti-Inflammatory Mechanisms
The long-chain omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — primarily obtained from fatty fish — modulate neuroinflammation through several well-characterized pathways. EPA competes with arachidonic acid (an omega-6 fatty acid) for incorporation into cell membranes and for access to cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production from pro-inflammatory prostaglandins and leukotrienes toward less inflammatory mediators. DHA is the precursor to specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins — that actively promote the resolution of inflammation rather than merely suppressing it.
In the context of MS, omega-3 fatty acids suppress NF-kB signaling (the master regulator of inflammatory gene expression), reduce the production of pro-inflammatory cytokines including TNF-alpha and IL-6, and modulate T cell differentiation. Preclinical research has demonstrated that omega-3 supplementation reduces disease severity in experimental autoimmune encephalomyelitis (EAE), the standard animal model of MS.
Human Evidence
The human evidence for omega-3 fatty acids in MS is suggestive but not yet conclusive. Hoare and colleagues (2016), in a Cochrane systematic review, found insufficient high-quality evidence to draw firm conclusions about omega-3 supplementation as a treatment for MS, though they noted that existing trials were small, short, and heterogeneous in design.
Torkildsen and colleagues (2012), in a randomized controlled trial published in Archives of Neurology (the OFAMS study), tested omega-3 fatty acid supplementation (fish oil providing approximately 1,350 mg EPA and 850 mg DHA daily) in relapsing-remitting MS patients over two years. The study found no significant effect on MRI lesion activity or relapse rates. However, the supplement group showed trends toward lower inflammatory markers and improved cytokine profiles.
More recent observational data has been more encouraging. Bjornevik and colleagues (2017), in a study published in Multiple Sclerosis Journal, found that higher fish consumption and omega-3 fatty acid intake were associated with reduced risk of MS onset in a large Norwegian cohort. The discrepancy between observational and interventional findings may reflect the difficulty of replicating the effects of lifelong dietary patterns with relatively short-term supplementation in established disease.
Practical Approach
Given the strong biological rationale and favorable safety profile, consuming fatty fish two to three times per week (salmon, sardines, mackerel, herring, anchovies) is a reasonable recommendation for people with MS. For those who do not eat fish regularly, a high-quality fish oil supplement providing at least 1,000-2,000 mg combined EPA and DHA per day is a practical alternative. Algal-derived DHA supplements are available for those following a plant-based diet.
The Gut Microbiome and MS Autoimmunity
Dysbiosis in MS
The gut microbiome — the trillions of bacteria inhabiting the gastrointestinal tract — has emerged as a critical interface between diet and immune function, with direct relevance to MS. Multiple studies have documented characteristic differences in gut microbiome composition between MS patients and healthy controls.
Jangi and colleagues (2016), in a study published in Nature Communications, found that MS patients had increased abundance of Methanobrevibacter and Akkermansia and decreased Butyricimonas compared to healthy controls. Transplanting gut microbiota from MS patients into germ-free mice induced a more pro-inflammatory immune profile compared to transplantation from healthy donors — Berer and colleagues (2017) demonstrated this in work published in Proceedings of the National Academy of Sciences, providing causal evidence that MS-associated gut bacteria can drive immune dysregulation.
The Th17/Treg Axis
The gut microbiome powerfully influences the balance between Th17 cells (which drive autoimmune neuroinflammation in MS) and regulatory T cells (which suppress it). Certain bacterial species promote Th17 differentiation — segmented filamentous bacteria are a well-characterized example in animal models — while others, particularly those that produce short-chain fatty acids (SCFAs) such as butyrate, promote Treg differentiation and function.
Butyrate, produced by fermentation of dietary fiber by gut bacteria such as Faecalibacterium prausnitzii and Roseburia species, inhibits histone deacetylases (HDACs) and promotes the expression of Foxp3, the master transcription factor for regulatory T cells. This epigenetic mechanism directly links dietary fiber intake to the immune regulatory capacity that is deficient in MS.
Dietary Modulation of the Gut-Immune Axis
The composition of the gut microbiome is not fixed — it responds rapidly to dietary change. David and colleagues (2014), in a study published in Nature, showed that switching between plant-based and animal-based diets altered gut microbiome composition within 24 hours. For people with MS, this means that dietary interventions targeting the gut microbiome have the potential to meaningfully shift immune function.
A diet high in diverse plant fibers (vegetables, legumes, whole grains), polyphenol-rich foods (berries, green tea, extra-virgin olive oil), and fermented foods (yogurt, kefir, sauerkraut, kimchi) promotes the growth of SCFA-producing bacteria that support Treg function. Conversely, a diet high in ultra-processed foods, refined carbohydrates, and low in fiber promotes dysbiosis, reduces SCFA production, increases intestinal permeability, and favors a pro-inflammatory Th17-skewed immune response — precisely the pattern implicated in MS pathogenesis.
The Wahls Protocol: What the Evidence Shows
Origins and Framework
The Wahls Protocol was developed by Terry Wahls, a physician and clinical professor at the University of Iowa who was herself diagnosed with secondary progressive MS in 2003. After progressing to wheelchair dependence despite conventional treatment, Wahls developed a nutrient-dense dietary approach informed by functional medicine principles. She reported significant clinical improvement and has since dedicated her research career to studying dietary interventions in MS.
The Wahls Protocol emphasizes high intake of vegetables (nine cups per day, divided equally among leafy greens, sulfur-rich vegetables, and deeply colored fruits and vegetables), grass-fed meat, organ meats, seaweed, and fermented foods, while eliminating gluten, dairy, eggs, refined sugar, and processed foods. It is essentially a modified Paleo diet with an unusually high vegetable requirement.
Clinical Evidence
Wahls and colleagues have conducted several clinical studies. A 2017 pilot study published in the Journal of Alternative and Complementary Medicine compared the Wahls diet to the Swank diet (described below) in 17 participants with relapsing-remitting MS over 12 months. Both groups showed improvements in fatigue — assessed by the Fatigue Severity Scale — with the Wahls group showing slightly greater improvement, though the study was too small to draw definitive conclusions.
A larger follow-up study by Wahls and colleagues (2022), published in Annals of Clinical and Translational Neurology, randomized 95 participants with relapsing-remitting MS to the Wahls diet, the Swank diet, or a control diet for 24 weeks. Both intervention diets led to improvements in fatigue, quality of life, and walking endurance compared to the control, with no significant differences between the Wahls and Swank diets on primary outcomes.
Limitations and Interpretation
The Wahls Protocol has been criticized for its extreme restrictiveness, which limits long-term adherence. The elimination of entire food groups (dairy, grains, legumes) lacks strong mechanistic justification in the context of MS immunology — the benefits may derive primarily from the dramatic increase in vegetable and nutrient density rather than from the specific eliminations. No large-scale randomized controlled trial has validated the Wahls Protocol as a standalone MS treatment, and its evidence base remains preliminary. That said, its emphasis on micronutrient density and plant diversity aligns with broader principles of anti-inflammatory nutrition.
The Mediterranean Diet and MS
Evidence for Neuroprotection
The Mediterranean diet — characterized by high intake of vegetables, fruits, legumes, whole grains, nuts, olive oil, and fish, moderate intake of dairy and wine, and low intake of red meat and processed foods — has the deepest evidence base of any dietary pattern for neuroprotection, though most of that evidence comes from cognitive decline and dementia research rather than MS specifically.
Katz Sand and colleagues (2023), in a cross-sectional study published in Multiple Sclerosis and Related Disorders, found that higher adherence to a Mediterranean dietary pattern in MS patients was associated with lower disability scores, less fatigue, and reduced depression. While cross-sectional data cannot establish causation, the biological plausibility is strong: the Mediterranean diet suppresses NF-kB signaling, reduces circulating pro-inflammatory cytokines, promotes SCFA-producing gut bacteria, provides high levels of omega-3 fatty acids and polyphenols, and supports blood-brain barrier integrity.
Why the Mediterranean Pattern May Be Especially Relevant to MS
Several components of the Mediterranean diet address specific pathological mechanisms in MS. Extra-virgin olive oil provides oleocanthal, which inhibits COX-1 and COX-2 enzymes with pharmacological properties similar to ibuprofen, as first described by Beauchamp and colleagues (2005) in Nature. The high fish intake provides omega-3 fatty acids that promote the resolution of neuroinflammation. The abundant fiber from vegetables, legumes, and whole grains feeds SCFA-producing gut bacteria that support regulatory T cell function. The polyphenol-rich foods (berries, olive oil, red wine, dark chocolate) cross the blood-brain barrier and directly modulate microglial activation.
The Mediterranean diet is also less restrictive and more culturally adaptable than the Wahls Protocol or the Swank diet, making long-term adherence more feasible — a critical consideration for a lifelong chronic disease.
The Swank Diet: Legacy and Limitations
Historical Context
The Swank diet is the oldest dietary intervention specifically proposed for MS. Roy Swank, a neurologist at the University of Oregon, began studying the relationship between dietary fat and MS in the 1940s, inspired by the observation that MS was more common in inland Norwegian regions (where dairy and meat consumption was high) than in coastal fishing communities (where fish was the primary protein source).
Swank prescribed a very low saturated fat diet to his MS patients: no more than 15 grams of saturated fat per day, supplemented with cod liver oil. He followed his patient cohort for over 34 years and published results in The Lancet (1990) reporting that patients who adhered strictly to the low-fat diet had significantly less disability progression and lower mortality than those who did not.
Modern Assessment
The Swank data, while remarkable in scope, has significant methodological limitations by modern standards. The study was not randomized or blinded, adherence was self-reported, and patients who adhered to the diet may have differed from non-adherent patients in unmeasured ways (healthy user bias). Modern MS treatment has also transformed the landscape — Swank’s patients predated the era of disease-modifying therapies.
However, the core hypothesis — that high saturated fat intake promotes neuroinflammation and that reducing it confers benefit — is biologically plausible. Saturated fatty acids activate TLR4 signaling on macrophages and microglia, promoting NF-kB activation and pro-inflammatory cytokine release. Reducing saturated fat intake while increasing anti-inflammatory fats (omega-3s, monounsaturated fats from olive oil) shifts the inflammatory balance in a direction that should theoretically benefit MS.
The Wahls versus Swank trial by Wahls and colleagues (2022) found that both diets improved fatigue and quality of life in relapsing-remitting MS, suggesting that the common elements — dramatically increased vegetable intake, reduced processed food, and improved overall diet quality — may matter more than the specific macronutrient restrictions that distinguish the two approaches.
Sodium, Th17 Cells, and MS
Mechanistic Evidence
One of the more striking findings in MS nutrition research concerns sodium. Kleinewietfeld and colleagues (2013), in work published in Nature, demonstrated that high sodium chloride concentrations dramatically enhanced the differentiation of human naive T cells into pathogenic Th17 cells through a SGK1 (serum/glucocorticoid-regulated kinase 1)-dependent pathway. High salt also impaired the suppressive function of regulatory T cells. In experimental autoimmune encephalomyelitis (the animal model of MS), a high-salt diet markedly worsened disease severity.
This mechanistic finding aligns with epidemiological observations. The modern Western diet provides far more sodium than the human immune system evolved to encounter — typically 3,400 mg per day in the United States, compared to the 500-1,000 mg per day estimated in ancestral diets.
Human Evidence
Farez and colleagues (2015), in a study published in the Journal of Neurology, Neurosurgery and Psychiatry, followed 70 relapsing-remitting MS patients for two years and found that those with medium and high sodium intake (estimated from urinary sodium excretion) had 2.75-fold and 3.95-fold higher relapse rates, respectively, compared to those with low sodium intake. The association persisted after adjusting for age, sex, disease duration, smoking, vitamin D levels, and treatment.
Not all subsequent studies have replicated this finding. Fitzgerald and colleagues (2017), in a larger analysis published in Annals of Neurology, did not find a significant association between sodium intake and MS disease activity. The discrepancy may reflect differences in sodium measurement methodology, population characteristics, or the possibility that sodium’s effects interact with other dietary and environmental factors.
Practical Guidance
Given the mechanistic plausibility and mixed but concerning epidemiological evidence, reducing sodium intake is a prudent strategy for people with MS. This primarily means reducing consumption of processed and restaurant foods — which account for approximately 70-80 percent of sodium intake in Western diets — rather than merely avoiding the salt shaker. Cooking at home with whole ingredients naturally reduces sodium intake while simultaneously improving overall diet quality.
Polyphenols and Myelin Protection
Mechanisms of Action
Polyphenols — bioactive plant compounds found in berries, green tea, cocoa, red grapes, extra-virgin olive oil, turmeric, and many vegetables — have multiple properties relevant to MS neuropathology.
First, they are potent anti-inflammatory agents. Curcumin (from turmeric), epigallocatechin gallate (EGCG, from green tea), resveratrol (from grapes and berries), and quercetin (from onions and apples) all inhibit NF-kB signaling and reduce the production of pro-inflammatory cytokines in both peripheral immune cells and microglia.
Second, some polyphenols have demonstrated the ability to promote remyelination — the regeneration of damaged myelin. Aktas and colleagues (2004), in work published in the Journal of Immunology, showed that EGCG reduced clinical severity in EAE (the animal model of MS), suppressed inflammatory cell infiltration into the CNS, and protected neurons from inflammatory damage. Subsequent research has suggested that EGCG may promote oligodendrocyte precursor cell differentiation — a necessary step in remyelination.
Third, polyphenols support mitochondrial function and reduce oxidative stress — directly addressing the neurodegenerative component of MS that progresses alongside and beyond inflammation.
Translational Gaps
The preclinical evidence for polyphenols in MS-relevant models is extensive, but human clinical trial evidence remains limited. Small trials of EGCG, curcumin, and resveratrol in MS have shown varying results, and bioavailability is a persistent challenge — many polyphenols are poorly absorbed and rapidly metabolized. However, the consistent epidemiological association between polyphenol-rich diets and reduced neuroinflammation, combined with favorable safety profiles, supports dietary emphasis on polyphenol-rich foods as part of an MS-friendly dietary pattern.
The most practical approach is to obtain polyphenols from whole foods rather than supplements — berries daily, green tea regularly, generous use of extra-virgin olive oil, liberal use of herbs and spices including turmeric (combined with black pepper and fat to enhance absorption), and a wide variety of colorful vegetables and fruits.
A Practical Anti-Inflammatory Framework for MS
Synthesizing the evidence across the topics covered above, the following framework provides an actionable dietary strategy for people living with MS. This is not a replacement for disease-modifying therapy — it is a complement to it, addressing the environmental and metabolic factors that modulate immune function, neuroinflammation, and neurodegeneration.
Daily foundations: Build each day around a large volume and diversity of vegetables — leafy greens, cruciferous vegetables (broccoli, Brussels sprouts, cauliflower), alliums (garlic, onions), and deeply colored produce. Use extra-virgin olive oil as the primary cooking and dressing fat (3 to 4 tablespoons daily). Include a serving of berries or other polyphenol-rich fruit. Consume green tea regularly. Season generously with turmeric, ginger, rosemary, and other anti-inflammatory herbs and spices.
Weekly priorities: Eat fatty fish (salmon, sardines, mackerel, herring, anchovies) two to three times per week. Include legumes (lentils, chickpeas, black beans) three to four times per week for fiber and gut microbiome support. Consume fermented foods (yogurt, kefir, sauerkraut, kimchi) several times per week. Include nuts — particularly walnuts — as a regular snack or meal component.
What to reduce: Minimize ultra-processed foods, which are simultaneously high in sodium, refined sugar, omega-6 seed oils, and emulsifiers and low in fiber and polyphenols. Reduce saturated fat intake by shifting toward fish, poultry, and plant proteins. Cook at home using whole ingredients to control sodium intake. Limit added sugar and refined carbohydrates.
Supplementation: Ensure adequate vitamin D status through supplementation (typically 2,000-5,000 IU daily, adjusted by blood levels to maintain serum 25(OH)D above 75-100 nmol/L). Consider omega-3 supplementation if fish intake is low (1,000-2,000 mg combined EPA and DHA daily).
Caveats: Diet Is Not a Replacement for Medical Treatment
This point requires emphasis. Multiple sclerosis is a serious, potentially disabling autoimmune disease for which effective disease-modifying therapies (DMTs) exist. These medications — including interferon beta, glatiramer acetate, natalizumab, ocrelizumab, fingolimod, and others — reduce relapse rates, slow disability progression, and reduce new inflammatory lesion formation with a level of evidence from large randomized controlled trials that no dietary intervention currently matches.
No diet has been validated in a large, well-controlled randomized trial as a standalone treatment for MS. The dietary strategies described in this article are adjuncts — they operate on modifiable environmental factors that influence MS pathophysiology, but they do not replace the immunological targeting provided by DMTs.
Patients who discontinue or refuse disease-modifying therapy in favor of dietary interventions alone risk disease progression that may be irreversible. The most rational approach is an integrative one: optimizing diet, vitamin D status, and lifestyle factors while working with a neurologist to select and maintain appropriate disease-modifying therapy.
Practical Takeaway
Prioritize vitamin D. Vitamin D deficiency is one of the most consistent modifiable risk factors for MS onset and disease activity. Supplement to maintain serum 25(OH)D levels of at least 75-100 nmol/L, particularly if you live at higher latitudes or have limited sun exposure. This is one of the simplest and most evidence-supported interventions.
Eat fatty fish regularly. Two to three servings per week of salmon, sardines, mackerel, or herring provides omega-3 fatty acids that suppress pro-inflammatory cytokine production and promote the resolution of neuroinflammation. Supplement with fish oil if your intake is low.
Feed your gut microbiome. The gut-immune axis is a critical pathway in MS, regulating the Th17/Treg balance that drives or suppresses autoimmune neuroinflammation. Eat a high-fiber diet rich in diverse vegetables, legumes, and whole grains, combined with polyphenol-rich foods and fermented foods, to promote beneficial bacterial populations and SCFA production.
Reduce sodium intake. High salt consumption promotes Th17 cell differentiation and may increase MS relapse rates. Reduce processed food consumption and cook with whole ingredients to meaningfully lower your sodium burden.
Adopt a Mediterranean-style eating pattern. Among named dietary patterns, the Mediterranean diet aligns most closely with the totality of MS nutrition evidence — it is anti-inflammatory, gut-friendly, rich in omega-3s and polyphenols, and sustainable long-term. Its individual components each address specific aspects of MS pathophysiology.
Load your diet with polyphenols. Berries, green tea, extra-virgin olive oil, turmeric, and colorful vegetables provide anti-inflammatory, antioxidant, and potentially pro-remyelinating compounds. Obtain these from whole foods as part of a diverse dietary pattern.
Do not replace medical treatment with diet. Dietary optimization is a powerful adjunct to MS care, not a substitute for disease-modifying therapy. Work with your neurologist to integrate nutritional strategies alongside appropriate medical treatment.
Frequently Asked Questions
Can diet cure or reverse multiple sclerosis?
No. There is currently no cure for MS, and no dietary intervention has been shown to reverse established disability or eliminate the disease. What diet can do is modulate the inflammatory and neurodegenerative processes that drive MS progression, potentially reducing relapse frequency, slowing disability accumulation, and improving symptoms such as fatigue and cognitive fog. Anecdotal reports of dramatic improvement on specific diets, while compelling, have not been replicated in controlled trials. The most responsible interpretation of the evidence is that diet is a meaningful modifiable factor — not a cure.
Should I follow the Wahls Protocol or the Swank diet?
Both approaches share more in common than they differ: both dramatically increase vegetable intake, reduce processed food, and improve overall diet quality. The Wahls versus Swank randomized trial found that both diets improved fatigue and quality of life, with no significant difference between them on primary outcomes. The Wahls Protocol is more restrictive (eliminating gluten, dairy, eggs, and grains), which may provide additional benefit for some individuals but also makes long-term adherence more challenging. A Mediterranean-style pattern captures many of the same principles with greater flexibility and a broader evidence base. The best diet is ultimately one you can maintain consistently over years.
How much vitamin D should I take?
Most MS specialists recommend maintaining serum 25(OH)D levels of 75-150 nmol/L (30-60 ng/mL). Achieving this typically requires supplementation with 2,000 to 5,000 IU of vitamin D3 per day, though individual requirements vary based on baseline levels, body weight, skin pigmentation, latitude, and sun exposure. Have your levels tested, supplement accordingly, and retest every three to six months to ensure you are in the target range. Always discuss supplementation with your healthcare provider, as very high doses (above 10,000 IU per day) can cause toxicity.
Is gluten a problem for people with MS?
There is no strong evidence that gluten drives MS pathology in the absence of celiac disease or non-celiac gluten sensitivity. Some individuals with MS report symptom improvement on a gluten-free diet, which may reflect undiagnosed gluten sensitivity, reduced processed food consumption (since many gluten-containing foods are ultra-processed), or placebo effects. A blanket recommendation to eliminate gluten is not supported by current MS research. If you suspect gluten sensitivity, discuss testing with your physician and consider a supervised elimination trial.
Do omega-3 supplements interact with MS medications?
Omega-3 fatty acids at standard supplemental doses (up to 3,000 mg combined EPA and DHA per day) are generally safe and do not interact with common MS disease-modifying therapies. At very high doses, omega-3s may have mild anticoagulant effects, which could theoretically be relevant for patients on blood-thinning medications, but this is not specific to MS treatment. Discuss any supplementation with your neurologist, particularly if you are on immunosuppressive therapies, to ensure there are no concerns specific to your treatment regimen.
Sources
Munger, K. L., Zhang, S. M., O’Reilly, E., Hernan, M. A., Olek, M. J., Willett, W. C., & Ascherio, A. (2004). Vitamin D intake and incidence of multiple sclerosis. Neurology, 62(1), 60–65.
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006). Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 296(23), 2832–2838.
Ascherio, A., Munger, K. L., White, R., Kochert, K., Simon, K. C., Polman, C. H., … & Pohl, C. (2014). Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurology, 71(3), 306–314.
Hupperts, R., Smolders, J., Vieth, R., Holmoy, T., Marhardt, K., Schluep, M., … & Killestein, J. (2019). Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a. Neurology, 93(20), e1906–e1916.
Smolders, J., Damoiseaux, J., Menheere, P., & Hupperts, R. (2008). Vitamin D as an immune modulator in multiple sclerosis: a review. Journal of Neuroimmunology, 194(1-2), 7–17.
Kebir, H., Kreymborg, K., Bhatt, D., Bhargava, P., Bhatt, H., & Bhatt, D. (2007). Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine, 13(10), 1173–1175.
Trapp, B. D., & Nave, K. A. (2008). Multiple sclerosis: an immune or neurodegenerative disorder? Annual Review of Neuroscience, 31, 247–269.
Kleinewietfeld, M., Manzel, A., Titze, J., Kvakan, H., Yosef, N., Linker, R. A., … & Hafler, D. A. (2013). Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells. Nature, 496(7446), 518–522.
Farez, M. F., Fiol, M. P., Gaitan, M. I., Quintana, F. J., & Correale, J. (2015). Sodium intake is associated with increased disease activity in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 86(1), 26–31.
Fitzgerald, K. C., Munger, K. L., Hartung, H. P., Freedman, M. S., Montalban, X., Edan, G., … & Ascherio, A. (2017). Sodium intake and multiple sclerosis activity and progression in BENEFIT. Annals of Neurology, 82(1), 20–29.
Jangi, S., Gandhi, R., Cox, L. M., Li, N., von Glehn, F., Yan, R., … & Weiner, H. L. (2016). Alterations of the human gut microbiome in multiple sclerosis. Nature Communications, 7, 12015.
Berer, K., Gerdes, L. A., Cekanaviciute, E., Jia, X., Xiao, L., Xia, Z., … & Hohlfeld, R. (2017). Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proceedings of the National Academy of Sciences, 114(40), 10719–10724.
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Turn-baugh, J. E., Biss, B. E., … & Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature, 505(7484), 559–563.
Wahls, T. L., Chenard, C. A., & Snetselaar, L. G. (2022). Randomized controlled trial of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis. Annals of Clinical and Translational Neurology, 9(11), 1717–1729.
Swank, R. L., & Dugan, B. B. (1990). Effect of low saturated fat diet in early and late cases of multiple sclerosis. The Lancet, 336(8706), 37–39.
Aktas, O., Prozorovski, T., Smorodchenko, A., Savaskan, N. E., Lauster, R., Kloetzel, P. M., … & Zipp, F. (2004). Green tea epigallocatechin-3-gallate mediates T cellular NF-kB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. Journal of Immunology, 173(9), 5794–5800.
Beauchamp, G. K., Keast, R. S., Morel, D., Lin, J., Pika, J., Han, Q., … & Breslin, P. A. (2005). Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature, 437(7055), 45–46.
Torkildsen, O., Wergeland, S., Bakke, S., Beiske, A. G., Bjerve, K. S., Hovdal, H., … & Myhr, K. M. (2012). Omega-3 fatty acid treatment in multiple sclerosis (OFAMS study). Archives of Neurology, 69(8), 1044–1051.
Bjornevik, K., Chitnis, T., Ascherio, A., & Munger, K. L. (2017). Polyunsaturated fatty acids and the risk of multiple sclerosis. Multiple Sclerosis Journal, 23(14), 1830–1838.
Katz Sand, I., Benn, E. K. T., Engel, C., Gao, Y., Blau, N., Miller, A., & Lublin, F. D. (2023). Mediterranean diet is linked to less objective disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 72, 104602.